Starlake Bioscience Co Inc Zhaoqing Guangdong

Star Lake Bioscience announced on September 24 that director and general manager Yan Xiaolin resigned from his positions as director, general manager, and member of the board's strategic development and ESG committee and nomination committee for personal reasons. After his resignation, he will not hold any position in the company or its controlled subsidiaries. Until a new general manager is appointed, director Chen Wu will act in the role of general manager. Earlier, on September 21, deputy general manager Yan Xiaolong had already resigned for personal reasons and will no longer hold any position in the company or its controlled subsidiaries. On May 19 this year, former chairman Liu Libin resigned due to job transfer, and on May 27 the board elected Chen Wu to act as chairman and legal representative. As a result, the company's two core positions of chairman and general manager are both currently in an acting capacity. Behind the intensive executive changes is a sharp decline in performance. The 2026 interim report shows that the company achieved operating revenue of 8.189 billion yuan in the first half of the year, a slight year-on-year increase of 0.36 percent, but net profit attributable to the parent company was only 70.7186 million yuan, down 91.54 percent year-on-year. Net profit after deducting non-recurring items was 55.2846 million yuan, down 93.14 percent year-on-year. The company said this was mainly due to the impact of market supply and demand, with sales prices of major products declining. Star Lake Bioscience operates in the biological fermentation industry, with main products including animal nutrition amino acids, food additives, plant nutrition organic fertilizers, and pharmaceutical intermediates. As of the close on September 24, Star Lake Bioscience reported 4.12 yuan per share, down 1.20 percent.

Star Lake Technology announced that company director and general manager Yan Xiaolin has resigned from his positions as director, general manager, member of the board's strategic development and ESG committee, and member of the board's nomination committee for personal reasons. Following this resignation, Yan Xiaolin will not hold any position in the company or its controlled subsidiaries.

Starlake Bioscience has released its 2026 interim report. Affected by lower selling prices for its main products, net profit attributable to shareholders of the listed company fell by more than 90% year on year in the first half. The financial report shows that in the first half of 2026, the company achieved operating revenue of 8.189 billion yuan, up 0.36% year on year. Net profit attributable to shareholders of the listed company was 70.72 million yuan, down 91.54% year on year. Non-GAAP net profit was 55.28 million yuan, down 93.14% from the same period last year. The company's operating cash flow swung from 614 million yuan in the same period last year to negative 791 million yuan, a year-on-year decrease of 228.82%, mainly because of increased purchases of raw materials during the period. Starlake Bioscience said the main reason for the decline in performance was that, affected by market supply and demand, selling prices for its main products such as monosodium glutamate and amino acids fell, causing overall profit to decline year on year.

Xinghu Technology disclosed its earnings forecast, expecting attributable net profit for the first half of 2026 to be between 60 million and 85 million yuan, a year-on-year decline of 89.84% to 92.83%. Deducted non-recurring net profit is expected to be between 43 million and 60 million yuan, a year-on-year decline of 92.55% to 94.66%. The company primarily focuses on the research, development, production, and sales of food additives, feed additives, and pharmaceutical intermediates and active pharmaceutical ingredients. The change in performance is mainly affected by market supply and demand dynamics, with sales prices of major products declining, leading to reduced product gross margins and an overall year-on-year decline in profit.